Reducing Uncertainty in Value-Based Pricing Using Evidence Development Agreements
- 1 November 2010
- journal article
- Published by Springer Science and Business Media LLC in Applied Health Economics and Health Policy
- Vol. 8 (6), 377-386
- https://doi.org/10.2165/11531160-000000000-00000
Abstract
No abstract availableKeywords
This publication has 11 references indexed in Scilit:
- Pros and cons of apomorphine and l-dopa continuous infusion in advanced Parkinson's diseaseParkinsonism & Related Disorders, 2009
- Systematic review of apomorphine infusion, levodopa infusion and deep brain stimulation in advanced Parkinson's diseaseParkinsonism & Related Disorders, 2009
- Short-term cost and health consequences of duodenal levodopa infusion in advanced Parkinson’s disease in SwedenApplied Health Economics and Health Policy, 2009
- Duodenal levodopa infusion for advanced Parkinson's disease: 12‐month treatment outcomeMovement Disorders, 2007
- OFT, VBP: QED?Health Economics, 2007
- Coverage with Evidence Development: An examination of conceptual and policy issuesInternational Journal of Technology Assessment in Health Care, 2007
- Duodenal levodopa infusion monotherapy vs oral polypharmacy in advanced Parkinson diseaseNeurology, 2005
- Treatment of Parkinson's disease: levodopa as the first choiceZeitschrift für Neurologie, 2002
- Resource use and costs in a Swedish cohort of patients with Parkinson's diseaseMovement Disorders, 2002
- How common are complications of Parkinson's disease?Zeitschrift für Neurologie, 2002